Qiagen Collaborates with Denovo Biopharma to Develop CDx Test for the Treatment of Diffuse Large B-Cell Lymphoma
Shots:
- The companies collaborated to develop a blood-based CDx test to identify patients expressing DGM1 & respond to Denovo’s DB102 for treatment of DLBCL
- Qiagen will develop a diagnostic assay to identify the DGM1 in DLBCL patients & develop a real-time qualitative PCR companion diagnostic for the QIAGEN Rotor-Gene Q MDx instrument and apply for PMA with the US FDA
- DB102 and the DGM1 marker are currently in a P-III (ENGINE) trial on newly diagnosed, high-risk DLBCL patients. Additionally, Qiagen is working under collaboration agreements with 25+ companies to develop and commercialize CDx tests & strengthen the precision therapies for patients benefit
Ref: Businesswire | Image: Qiagen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com